Rovaldi Christopher 4
4 · Keros Therapeutics, Inc. · Filed Apr 8, 2022
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2022-04-06$16.00/sh+1,728$27,648→ 1,728 total - Sale
Common Stock
2022-04-06$65.00/sh−1,728$112,320→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-06−1,728→ 8,002 totalExercise: $16.00Exp: 2030-04-07→ Common Stock (1,728 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.